Molecular Imaging Program, NCI, NIH, Bethesda, Maryland.
Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland.
Clin Cancer Res. 2020 Jun 1;26(11):2573-2581. doi: 10.1158/1078-0432.CCR-19-2897. Epub 2020 Feb 7.
Trials of adoptive natural killer (NK)-cell immunotherapy for hematologic malignancies have thus far shown only marginal effects, despite the potent antitumor activity of these cells. Homing of infused cells to tumor microenvironments is critical for efficacy, but has not been well characterized. We established a novel method to track and quantify the distribution of adoptively transferred NK cells using rhesus macaques (RM) as a clinically relevant preclinical model.
RM NK cells were expanded for 14-21 days, labeled with Zr-oxine complex, and assessed for phenotype, function, and survival. Trafficking of Zr-labeled -expanded NK cells infused into RMs was monitored and quantitated by serial positron emission tomography (PET)/CT ( = 3, 2.05 ± 0.72 MBq, 23.5 ± 2.0 × 10 NK cells/kg) and compared with that of Zr-labeled nonexpanded NK cells, apoptotic NK cells, and hematopoietic stem and progenitor cells (HSPC).
NK cells retained sufficient levels of Zr for accurate tracking for 7 days. Zr labeling did not alter cellular phenotype, viability, or function. PET/CT showed NK cells initially localized in the lungs, followed by their migration to the liver, spleen, and, at low levels, bone marrow. One day following transfer, only 3.4% of infused NK cells localized to the BM versus 22.1% of HSPCs. No clinical side effects were observed, and dosimetry analysis indicated low organ radioexposures of 6.24 mSv/MBq (spleen) or lower.
These data support translation of this technique to humans to track the distribution of adoptively infused cells and to develop novel techniques to improve immune cell homing to tumor microenvironments.
尽管这些细胞具有强大的抗肿瘤活性,但迄今为止,用于血液恶性肿瘤的过继自然杀伤 (NK) 细胞免疫疗法的试验仅显示出边际效果。输注细胞向肿瘤微环境的归巢对于疗效至关重要,但尚未得到很好的描述。我们建立了一种使用恒河猴 (RM) 作为临床相关临床前模型来跟踪和量化过继转移 NK 细胞分布的新方法。
将 RMNK 细胞扩增 14-21 天,用 Zr-oxine 复合物标记,并评估表型、功能和存活情况。通过连续正电子发射断层扫描 (PET)/CT(= 3,2.05 ± 0.72 MBq,23.5 ± 2.0 × 10 NK 细胞/kg)监测和量化输注到 RM 中的 Zr 标记的扩增 NK 细胞的迁移,并将其与 Zr 标记的未扩增 NK 细胞、凋亡 NK 细胞和造血干细胞和祖细胞 (HSPC) 进行比较。
NK 细胞保留了足够水平的 Zr 以进行准确的 7 天跟踪。Zr 标记不会改变细胞表型、活力或功能。PET/CT 显示 NK 细胞最初定位于肺部,然后迁移到肝脏、脾脏,并且在低水平下定位于骨髓。转移后 1 天,只有 3.4%的输注 NK 细胞定位于 BM,而 22.1%的 HSPC 定位于 BM。未观察到临床副作用,剂量测定分析表明,器官放射性暴露低,脾脏为 6.24 mSv/MBq 或更低。
这些数据支持将该技术转化为人类,以跟踪过继输注细胞的分布,并开发新的技术来改善免疫细胞向肿瘤微环境的归巢。